Literature DB >> 10510335

The soluble CD40 ligand sCD154 in systemic lupus erythematosus.

K Kato1, E Santana-Sahagún, L Z Rassenti, M H Weisman, N Tamura, S Kobayashi, H Hashimoto, T J Kipps.   

Abstract

We found that the plasma of patients with active systemic lupus erythematosus (SLE) could induce a human B-cell line (Ramos) to express high levels of immune accessory molecules that are commonly found on blood B cells of patients with active SLE. The ability of SLE plasma to induce such phenotypic changes could be abrogated by neutralizing antibodies specific for the CD40 ligand (CD154) but not by antibodies to TNF-alpha. Immunoprecipitation studies with anti-CD154 identified a 20-kDa protein in the plasma of SLE patients with active disease, but not in plasma of normal donors, indicating that such plasma contained soluble CD154 (sCD154). Using a quantitative ELISA method, we found that the plasma of patients with active disease had levels of sCD154 that were significantly higher than those found in plasma of normal donors. Levels of CD154 transcripts in SLE blood lymphocytes correlated with the relative concentrations of sCD154 found in SLE plasma. Furthermore, plasma levels of sCD154 correlated with the titers of anti-double-stranded DNA autoantibody and with clinical disease activity. These studies indicate that sCD154 of patients with SLE may act as a functional ligand for CD40 that is associated with SLE disease activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10510335      PMCID: PMC408556          DOI: 10.1172/JCI7014

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells.

Authors:  R J Noelle; M Roy; D M Shepherd; I Stamenkovic; J A Ledbetter; A Aruffo
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

2.  Expression of a 32-kDa ligand for the CD40 antigen on activated human T lymphocytes.

Authors:  P Hermann; D Blanchard; B de Saint-Vis; F Fossiez; C Gaillard; B Vanbervliet; F Brière; J Banchereau; J P Galizzi
Journal:  Eur J Immunol       Date:  1993-04       Impact factor: 5.532

3.  Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus.

Authors:  A J Swaak; L A Aarden; L W Statius van Eps; T E Feltkamp
Journal:  Arthritis Rheum       Date:  1979-03

4.  A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF.

Authors:  M Kriegler; C Perez; K DeFay; I Albert; S D Lu
Journal:  Cell       Date:  1988-04-08       Impact factor: 41.582

5.  Evidence for the existence of two forms of membrane tumor necrosis factor: an integral protein and a molecule attached to its receptor.

Authors:  B Luettig; T Decker; M L Lohmann-Matthes
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

6.  Molecular and biological characterization of a murine ligand for CD40.

Authors:  R J Armitage; W C Fanslow; L Strockbine; T A Sato; K N Clifford; B M Macduff; D M Anderson; S D Gimpel; T Davis-Smith; C R Maliszewski
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

7.  Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus.

Authors:  M H Liang; S A Socher; M G Larson; P H Schur
Journal:  Arthritis Rheum       Date:  1989-09

8.  Expression of costimulatory molecule CD80 on peripheral blood T cells in patients with systemic lupus erythematosus.

Authors:  Y Takasaki; M Ogaki; K Abe; K Takeuchi; S Ando; Y Tokano; S Kobayashi; I Sekigawa; H Tsuda; H Hashimoto
Journal:  J Rheumatol       Date:  1998-06       Impact factor: 4.666

9.  CTLA-4 is a second receptor for the B cell activation antigen B7.

Authors:  P S Linsley; W Brady; M Urnes; L S Grosmaire; N K Damle; J A Ledbetter
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

10.  Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal.

Authors:  E A Ranheim; T J Kipps
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

View more
  47 in total

Review 1.  Targeting CD40L: a promising therapeutic approach.

Authors:  Dimitris Daoussis; Andrew P Andonopoulos; Stamatis-Nick C Liossis
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

Review 2.  New molecular targets for treatment of lymphoma.

Authors:  Barbara Pro; Anas Younes
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

Review 3.  Modification of accessory molecule signaling.

Authors:  Mary K Crow
Journal:  Springer Semin Immunopathol       Date:  2006-05-16

4.  Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154.

Authors:  He Xu; Xiaojie Zhang; Roslyn B Mannon; Allan D Kirk
Journal:  J Clin Invest       Date:  2006-02-23       Impact factor: 14.808

5.  Developmental changes in soluble CD40 ligand.

Authors:  Jill M Cholette; Neil Blumberg; Richard P Phipps; Michael P McDermott; Kelly F Gettings; Norma B Lerner
Journal:  J Pediatr       Date:  2007-10-24       Impact factor: 4.406

6.  Platelet and soluble CD40L in meningococcal sepsis.

Authors:  David P Inwald; Saul N Faust; Paula Lister; Mark J Peters; Michael Levin; Robert Heyderman; Nigel J Klein
Journal:  Intensive Care Med       Date:  2006-06-30       Impact factor: 17.440

7.  Naive CD4 T cells constitutively express CD40L and augment autoreactive B cell survival.

Authors:  Robin Lesley; Lisa M Kelly; Ying Xu; Jason G Cyster
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-30       Impact factor: 11.205

8.  Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients.

Authors:  S Danese; J A Katz; S Saibeni; A Papa; A Gasbarrini; M Vecchi; C Fiocchi
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

Review 9.  Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future.

Authors:  Noam Jacob; William Stohl
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

Review 10.  B-cell-targeted therapies in systemic lupus erythematosus.

Authors:  Vera Sau-Fong Chan; Helen Hoi-Lun Tsang; Rachel Chun-Yee Tam; Liwei Lu; Chak-Sing Lau
Journal:  Cell Mol Immunol       Date:  2013-01-28       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.